



30<sup>th</sup> May, 2022

**The Deputy Manager,**  
Department of Corporate Services,  
**BSE Limited,**  
P.J. Towers, Dalal Street, Fort,  
Mumbai - 400001.

Scrip Code: 507486 (BSE)

Dear Sir,

**Subject: Outcome of the Board Meeting held on Monday, 30<sup>th</sup> May, 2022**

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Monday, 30<sup>th</sup> May, 2022 inter alia, has approved the following:

**(a) Approval of Audited Financial Results of the Company for the Fourth Quarter and Financial Year ended 31<sup>st</sup> March, 2022:**

Upon recommendation of the Audit Committee, the Board of Directors has approved the Audited Financial Results as per Indian Accounting Standards (IND AS) for the Quarter and Financial Year ended 31<sup>st</sup> March, 2022.

Accordingly, please find enclose herewith:

- (i) Audited Financial Results for the year ended 31<sup>st</sup> March, 2022; and
- (ii) Statutory Auditors Report on the Audited Financial Results for the year ended 31<sup>st</sup> March, 2022

The Report of the Statutory Auditors is with an unmodified opinion with respect to the Audited Financial Results of the Company for the Quarter and Financial Year ended 31<sup>st</sup> March, 2022.



Kindly take the same on your record and oblige.

This is for the information of members.

Thanking you,

Yours Faithfully,

For Caprolactam Chemical Limited

Zaver S. Bhanushali  
Managing Director  
DIN: 00663374






CIN No. L24110MH1988PLC049683

(Rs. In Lakhs )

PART 1		Standalone				
Sr. No	PARTICULARS	Three Months Ended			Year Ended	
		31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	<b>Income form Operations</b>					
	a) Revenue from Operations	62.82	15.56	159.51	206.88	630.91
	b) Other Operating Income	-	-	-	-	-
	c) Other Income	16.11	2.24	3.58	40.56	9.32
	<b>Total income (Net)</b>	<b>78.93</b>	<b>17.81</b>	<b>163.09</b>	<b>247.44</b>	<b>640.22</b>
2	<b>Expenses</b>					
	a) Cost of Materials consumed	13.95	3.06	1.21	55.43	13.42
	b) Purchase of traded goods	-	-	-	-	-
	c) Changes in inventories of finished	(0.77)	47.16	(0.36)	(2.13)	(0.36)
	d) Employees benefit expense	8.81	5.64	5.51	25.44	30.99
	e) Finance Cost	6.13	7.78	6.73	27.64	29.69
	f) Depreciation & amortisation expenses	30.52	25.54	35.77	103.47	106.55
	g) Other Expenses	32.78	4.61	122.89	184.99	370.81
	<b>Total Expenses</b>	<b>91.42</b>	<b>93.80</b>	<b>171.75</b>	<b>394.84</b>	<b>551.10</b>
3	Profit/(Loss) from Operations before exceptional items & tax (1 - 2 )	<b>(12.49)</b>	<b>(75.99)</b>	<b>(8.67)</b>	<b>(147.40)</b>	<b>89.12</b>
4	Exceptional Item	-	-	-	-	-
5	Profit/(Loss) from Operations after exceptional items & before tax (3 - 4 )	<b>(12.49)</b>	<b>(75.99)</b>	<b>(8.67)</b>	<b>(147.40)</b>	<b>89.12</b>
6	Tax Expense					
	a) Current Tax	-	-	27.13	-	27.13
	b) Deferred Tax	(14.00)	4.97	(3.06)	(19.19)	(3.06)
7	Profit from ordinary activities (after tax) for the period ( 5 - 6 )	<b>(14.00)</b>	<b>(80.96)</b>	<b>24.07</b>	<b>(19.19)</b>	<b>24.07</b>
8	Extra Ordinary Items ( net of taxes)	-	-	-	-	-
9	Net Profit for the period (7+ 8 )	<b>1.51</b>	<b>(80.96)</b>	<b>(32.73)</b>	<b>(128.21)</b>	<b>65.05</b>
10	Other Comprehensive Income/(Expenses) net of tax					
	a) Items that will not be reclassified to profit or Loss	-	-	-	-	-
	b) Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	<b>1.51</b>	<b>(80.96)</b>	<b>(32.73)</b>	<b>(128.21)</b>	<b>65.05</b>
12	Paid-up equity share capital ( Face value of Rs. 1/- each)	460.00	460.00	460.00	460.00	460.00
	Face Vlue of Equity share capital	10.00	10.00	10.00	10.00	10.00
13	Reserve excluding Revatuation Reserves				(180.20)	(51.99)
14	Earning Per Share (EPS) basic & diluted					
	(a) Before Extraordinary items	0.03	(1.76)	(0.71)	(2.79)	1.41
	(b) After Extraordinary items	0.03	(1.76)	(0.71)	(2.79)	1.41
Notes :						

Notes :

Mehta   



1. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 30th May, 2022. There are no qualifications in the audit report for the year ended 31st March, 2022.
2. The Company, on standalone basis, has only one segment of activity namely "Manufacturing and selling of Chemicals", the disclosure requirement of the Indian Accounting Standard (AS) 108 "Operating Segment" notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rule, 2014 are not applicable.
3. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third quarter of the respective financial year.
4. The statutory Auditor have expressed an unmodified audit opinion.
5. The figures of the previous year have been regrouped /rearranged, wherever considered necessary, to make them comparable with the figures for the current year.
6. The Standalone results of the Company are available on the Company's website <http://caprolactam.co.in/> and also available on the websites of the BSE Ltd and National Stock Exchange of India Ltd..

As per attached report of even date.

**For Pulindra Patel & Co.**

**Chartered Accountants**

**ICAI Firm Registration No. 115187W**

**Pulindra Patel**

**Proprietor**

**Mem No. : 048991**


**UDIN :**

**Place : Mahad**


**Date : 30th May, 2022**

**For and on behalf of the Board of Directors**


**Company Secretary Caprolactam Chemicals Limited**



**Dolly Dipen Mehta**  
**M.N.A38116**




**Mrs. Z. S. Bhanushali**  
**Managing Director**  
**DIN- 00663374**



**Mr. S. S. Bhanushali**  
**Director**  
**DIN- 01721586**

**Place: Mahad**

**Date : 30th May, 2022**





**Caprolactam Chemicals Limited**  
CIN No. L24110MH1988PLC049683


**Standalone Statement of Assets and Liabilities as at 31st March, 2022**

Rs. In Lakhs

	Particulars	Standalone	
		Year Ended 31 March 2022 Audited	Year Ended 31 March 2021 Audited
<b>I</b>	<b>ASSETS</b>		
	<b>1. Non-current Assets</b>		
	(a) Property, plant and equipment	525.57	549.74
	(b) Capital work-in-progress	396.14	-
	(c) Right of use assets	-	-
	(f) Financial Assets		
	iii) Other Financial Assets	11.09	10.57
	<b>Total Non-current assets</b>	<b>932.79</b>	<b>560.31</b>
	<b>2. Current Assets</b>		
	(a) Inventories	12.22	10.74
	(b) Financial Assets		
	ii) Trade Receivables	3.27	47.04
	iii) Cash & cash equivalents	14.73	52.04
	(c) Other current assets	70.36	49.46
	<b>Total current assets</b>	<b>100.58</b>	<b>159.28</b>
	<b>TOTAL ASSETS</b>	<b>1,033.37</b>	<b>719.59</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>1. Equity</b>		
	(a) Equity share capital	460.00	460.00
	(b) Other equity	(180.20)	(51.99)
	<b>Total Equity</b>	<b>279.80</b>	<b>408.01</b>
	<b>2. Non current liabilities</b>		
	(a) Financial Liabilities		
	Borrowing	275.45	-
	(b) Deferred tax liabilities (Net)	1.07	20.26
	<b>Total non current liabilities</b>	<b>276.52</b>	<b>20.26</b>
	<b>3. Current Liabilities</b>		
	(a) Financial Liabilities		
	i) Borrowings	99.88	215.00
	ii) Trade Payables	-	-
	a) Outstanding dues of micro & small enterprises	1.26	-
	b) Outstanding dues other than micro & small enterprises	48.53	40.01
	iii) Other Current Liabilities	325.54	9.18
	(b) Employee benefit obligation	1.82	-
	(c) Income Tax Liabilities (net)	-	27.13
	<b>Total current liabilities</b>	<b>477.05</b>	<b>291.32</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,033.37</b>	<b>719.59</b>

*Dehta*

*S. S. Chaudhary*



*SPB*



**Notes :**

1. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 30th May, 2022. There are no qualifications in the audit report for the year ended 31st March, 2022.
2. The Company, on standalone basis, has only one segment of activity namely "Manufacturing and selling of Chemicals", the disclosure requirement of the Indian Accounting Standard (AS) 108 "Operating Segment" notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rule, 2014 are not applicable.
3. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third quarter of the respective financial year.
4. The statutory Auditor have expressed an unmodified audit opinion.
5. The figures of the previous year have been regrouped /rearranged, wherever considered necessary, to make them comparable with the figures for the current year.
6. The Standalone results of the Company are available on the Company's website <http://caprolactam.co.in/> and also available on the websites of the BSE Ltd and National Stock Exchange of India Ltd..

As per attached report of even date.

**For Pulindra Patel & Co.**

**Chartered Accountants**

**ICAI Firm Registration No. 115187W**

**Pulindra Patel**

**Proprietor**


**Mem No. : 048991**

**UDIN :**

**Place : Mahad**


**Date : 30th May, 2022**

**Company Secretary Caprolactam Chemicals Limited**




**Dolly Dipen Mehta**  
**M.N.A38116**

**For and on behalf of the Board of Directors**




**Mrs. Z. S. Bhanushali**  
**Managing Director**  
**DIN- 00663374**



**Mr. S. S. Bhanushali**  
**Director**  
**DIN- 01721586**

**Place: Mahad**

**Date : 30th May, 2022**







**PULINDRA PATEL & CO.**  
**CHARTERED ACCOUNTANTS**

Office No. A-1004, Paras Business Center, Near Borivali Station East, Kasturba Road No.1,  
Borivali (East), Mumbai – 66,  
Office (Tel) + 022 28069664, 022-22056233, 022-68844594, +91 9322268243, Office (M) + 91 9619908533  
Email : caoffice@pulindrapatel.com,

**Independent Auditor's Report on Annual Financial Results of Caprolactam Chemicals Limited Pursuant To Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Review Report to  
The Board of Directors,  
Caprolactam Chemicals Limited  
Plot No. B-31, M.I.D.C.- Mahad,  
Taluka – Mahad,  
Dist Raigad – 402302

**Opinion**

We have audited the accompanying statement of standalone financial results of CAPROLACTAM CHEMICALS LIMITED (the company) for the, Quarter and year ended March 31, 2022 (“the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) is presented in accordance with requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended in this regard; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the quarter and the year ended March 31, 2022.





## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics issued by ICAI. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Management's Responsibilities for the Standalone Financial Results**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Act read with the relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.





## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.





- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matters

The Statement includes the results for the quarter ended March 31, 2022 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year.

Yours faithfully,  
For PULINDRA PATEL & Co.  
Chartered Accountants  
ICAI Firm Registration No. 115187W

  
(Pulindra Patel)  
Proprietor  
Membership No. 048991  
UDIN : 22048991AJVSHI8159



Place : Mumbai  
Date : 30<sup>th</sup> May, 2022



**Caprolactam Chemicals Limited**  
CIN No. L24110MH1988PLC049683

**Audited Standalone Statement of Cash Flow for the year ended 31st March, 2022**

(Rs. In Lakhs)

PARTICULARS	Standalone	
	Year Ended	
	31-Mar-22 Audited	31-Mar-21 Audited
<b>Cash flow from operating activities</b>		
Profit before Income tax	(147.40)	89.12
Adjustment for:		
Depreciation and amortisation expenses	103.47	106.55
Interest income classified as investing cash flows	(0.55)	(1.39)
Finance Cost	27.64	29.68
<b>Cash generated from operations before working capital changes</b>	<b>(16.84)</b>	<b>223.97</b>
<b>Change in operating assets and liabilities:</b>		
Decrease/(Increase) in inventories	(1.48)	(2.52)
Decrease/(Increase) in non current financial assets	(0.51)	2.88
Decrease/(Increase) in other current assets	(15.88)	(21.65)
Decrease/(Increase) in trade receivables	43.77	(17.04)
Decrease/(Increase) in trade payables	9.79	(10.21)
Increase/decrease in Employee benefit obligation	1.82	-
Decrease/(Increase) in current financial liabilities	316.36	(2.32)
	<b>353.88</b>	<b>(50.85)</b>
<b>Cash generated from operating activities</b>	<b>337.04</b>	<b>173.12</b>
Taxes paid net of refunds	(32.15)	(47.65)
<b>Net cash flow from operating activities (A)</b>	<b>304.89</b>	<b>125.47</b>
<b>Cash flow from investing activities</b>		
Purchase of property, plant and equipments including work in progress	(475.44)	(49.22)
Interest received	0.55	1.39
<b>Net cash flow from investing activities (B)</b>	<b>(474.89)</b>	<b>(47.83)</b>
<b>Cash flow from financing activities</b>		
(Repayment)/proceeds of short term borrowings, net	160.33	(29.71)
Interest paid	(27.64)	(29.68)
<b>Net cash flow from financing activities (C)</b>	<b>132.69</b>	<b>(59.40)</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>(37.30)</b>	<b>18.23</b>
Cash and cash equivalents at the beginning of the financial year	52.04	33.80
Cash and cash equivalents at the year end	<b>14.73</b>	<b>52.04</b>

**Notes:-**

- Cash flow statement has been prepared under Indirect method as set out in Ind AS 7 as per the Companies (Indian Accounting Standards) Rule 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rule, 2016.
- Previous years figures have been restated and regrouped wherever necessary.
- Figures in bracket indicates cash outflow.
- Components of cash and cash equivalents at the year end comprise of;

As per attached report of even date.

**For Pulindra Patel & Co.**  
Chartered Accountants  
ICAI Firm Registration No. 115187W

Pulindra Patel  
Proprietor  
Mem No. : 048991  
UDIN :  
Place : Mahad  
Date : 30th May, 2022

**For and on behalf of the Board of Directors**  
**Company Secretary Caprolactam Chemicals Limited**

**Dolly Dipen Mehta**  
M.N.A38116

**Mrs. Z. S. Bhanushali**  
Managing Director  
DIN- 00663374

**Mr. S. S. Bhanushali**  
Director  
DIN- 01721586

Place: Mahad  
Date : 30th May, 2022

